Ruxolitinib
- TRADE NAME: Jakafi (Incyte)
- INDICATIONS: Intermediate or high-risk myelofibrosis; polycythemia vera
- CLASS: Janus kinase (JAK) inhibitor
- HALF-LIFE: 3 hours
Boceprevir, Clarithromycin, Conivaptan, Fluconazole, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mibefradil, Nefazodone, Nelfinavir, Posaconazole, Ritonavir, Ritonavir, Saquinavir, Strong CYP3A4 inhibitors, Telaprevir, Telithromycin, Voriconazole
PREGNANCY CATEGORY: C
BOXED WARNING (ADDED MARCH 2023) (FOR THE TOPICAL FORMULATION OF RUXOLITINIB APPROVED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS AND NONSEGMENTAL VITILIGO).
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING.
SERIOUS INFECTIONS LEADING TO HOSPITALIZATION OR DEATH, INCLUDING TUBERCULOSIS AND BACTERIAL, INVASIVE FUNGAL, VIRAL, AND OTHER OPPORTUNISTIC INFECTIONS, HAVE OCCURRED IN PATIENTS RECEIVING JANUS KINASE INHIBITORS FOR INFLAMMATORY CONDITIONS.
HIGHER RATE OF ALL-CAUSE MORTALITY, INCLUDING SUDDEN CARDIOVASCULAR DEATH HAVE BEEN OBSERVED IN PATIENTS TREATED WITH JANUS KINASE INHIBITORS FOR INFLAMMATORY CONDITIONS.
LYMPHOMA AND OTHER MALIGNANCIES HAVE BEEN OBSERVED IN PATIENTS TREATED WITH JANUS KINASE INHIBITORS FOR INFLAMMATORY CONDITIONS.
HIGHER RATE OF MACE (INCLUDING CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE) HAS BEEN OBSERVED IN PATIENTS TREATED WITH JANUS KINASE INHIBITORS FOR INFLAMMATORY CONDITIONS.
THROMBOSIS, INCLUDING DEEP VENOUS THROMBOSIS, PULMONARY EMBOLISM, AND ARTERIAL THROMBOSIS, SOME FATAL, HAVE OCCURRED IN PATIENTS TREATED WITH JANUS KINASE INHIBITORS FOR INFLAMMATORY CONDITIONS.
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ruxolitinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 12/03/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric